SPY330.06+1.27 0.39%
DIA268.41+1.69 0.63%
IXIC10,941.17+38.37 0.35%

Citi Maintains Buy on ProQR Therapeutics, Lowers Price Target to $33

Citi maintains ProQR Therapeutics (NASDAQ:PRQR) with a Buy and lowers the price target from $40 to $33.

Benzinga · -

Citi maintains ProQR Therapeutics (NASDAQ:PRQR) with a Buy and lowers the price target from $40 to $33.